249 related articles for article (PubMed ID: 27797294)
21. Stromal CYR61 Confers Resistance to Mitoxantrone via Spleen Tyrosine Kinase Activation in Human Acute Myeloid Leukaemia.
Long X; Yu Y; Perlaky L; Man TK; Redell MS
Br J Haematol; 2015 Sep; 170(5):704-18. PubMed ID: 25974135
[TBL] [Abstract][Full Text] [Related]
22. Chemotherapeutic treatment of bone marrow stromal cells strongly affects their protective effect on acute myeloid leukemia cell survival.
Moshaver B; van der Pol MA; Westra AH; Ossenkoppele GJ; Zweegman S; Schuurhuis GJ
Leuk Lymphoma; 2008 Jan; 49(1):134-48. PubMed ID: 17926185
[TBL] [Abstract][Full Text] [Related]
23. DNA damage to bone marrow stromal cells by antileukemia drugs induces chemoresistance in acute myeloid leukemia via paracrine FGF10-FGFR2 signaling.
Yu S; Ye J; Wang Y; Lu T; Liu Y; Liu N; Zhang J; Lu F; Ma D; Gale RP; Ji C
J Biol Chem; 2023 Jan; 299(1):102787. PubMed ID: 36509141
[TBL] [Abstract][Full Text] [Related]
24. AMPK-ULK1-Mediated Autophagy Confers Resistance to BET Inhibitor JQ1 in Acute Myeloid Leukemia Stem Cells.
Jang JE; Eom JI; Jeung HK; Cheong JW; Lee JY; Kim JS; Min YH
Clin Cancer Res; 2017 Jun; 23(11):2781-2794. PubMed ID: 27864418
[No Abstract] [Full Text] [Related]
25. Targeting AMPK-ULK1-mediated autophagy for combating BET inhibitor resistance in acute myeloid leukemia stem cells.
Jang JE; Eom JI; Jeung HK; Cheong JW; Lee JY; Kim JS; Min YH
Autophagy; 2017 Apr; 13(4):761-762. PubMed ID: 28118076
[TBL] [Abstract][Full Text] [Related]
26. Impact of loss of BH3-only proteins on the development and treatment of MLL-fusion gene-driven AML in mice.
Bilardi RA; Anstee NS; Glaser SP; Robati M; Vandenberg CJ; Cory S
Cell Death Dis; 2016 Sep; 7(9):e2351. PubMed ID: 27584789
[TBL] [Abstract][Full Text] [Related]
27. The small-molecule compound AC-73 targeting CD147 inhibits leukemic cell proliferation, induces autophagy and increases the chemotherapeutic sensitivity of acute myeloid leukemia cells.
Spinello I; Saulle E; Quaranta MT; Pasquini L; Pelosi E; Castelli G; Ottone T; Voso MT; Testa U; Labbaye C
Haematologica; 2019 May; 104(5):973-985. PubMed ID: 30467201
[TBL] [Abstract][Full Text] [Related]
28. Emodin and Its Combination with Cytarabine Induce Apoptosis in Resistant Acute Myeloid Leukemia Cells in Vitro and in Vivo.
Chen Y; Gan D; Huang Q; Luo X; Lin D; Hu J
Cell Physiol Biochem; 2018; 48(5):2061-2073. PubMed ID: 30099447
[TBL] [Abstract][Full Text] [Related]
29. Notch signalling drives bone marrow stromal cell-mediated chemoresistance in acute myeloid leukemia.
Takam Kamga P; Bassi G; Cassaro A; Midolo M; Di Trapani M; Gatti A; Carusone R; Resci F; Perbellini O; Gottardi M; Bonifacio M; Nwabo Kamdje AH; Ambrosetti A; Krampera M
Oncotarget; 2016 Apr; 7(16):21713-27. PubMed ID: 26967055
[TBL] [Abstract][Full Text] [Related]
30. The Complexity of Targeting PI3K-Akt-mTOR Signalling in Human Acute Myeloid Leukaemia: The Importance of Leukemic Cell Heterogeneity, Neighbouring Mesenchymal Stem Cells and Immunocompetent Cells.
Brenner AK; Andersson Tvedt TH; Bruserud Ø
Molecules; 2016 Nov; 21(11):. PubMed ID: 27845732
[TBL] [Abstract][Full Text] [Related]
31. TGF-β1 and CXCL12 modulate proliferation and chemotherapy sensitivity of acute myeloid leukemia cells co-cultured with multipotent mesenchymal stromal cells.
Schelker RC; Iberl S; Müller G; Hart C; Herr W; Grassinger J
Hematology; 2018 Jul; 23(6):337-345. PubMed ID: 29140182
[TBL] [Abstract][Full Text] [Related]
32. The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells.
Nechiporuk T; Kurtz SE; Nikolova O; Liu T; Jones CL; D'Alessandro A; Culp-Hill R; d'Almeida A; Joshi SK; Rosenberg M; Tognon CE; Danilov AV; Druker BJ; Chang BH; McWeeney SK; Tyner JW
Cancer Discov; 2019 Jul; 9(7):910-925. PubMed ID: 31048320
[TBL] [Abstract][Full Text] [Related]
33. Repression of Mcl-1 expression by the CDC7/CDK9 inhibitor PHA-767491 overcomes bone marrow stroma-mediated drug resistance in AML.
O' Reilly E; Dhami SPS; Baev DV; Ortutay C; Halpin-McCormick A; Morrell R; Santocanale C; Samali A; Quinn J; O'Dwyer ME; Szegezdi E
Sci Rep; 2018 Oct; 8(1):15752. PubMed ID: 30361682
[TBL] [Abstract][Full Text] [Related]
34. Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.
Teh TC; Nguyen NY; Moujalled DM; Segal D; Pomilio G; Rijal S; Jabbour A; Cummins K; Lackovic K; Blombery P; Thompson E; Ekert PG; Lessene G; Glaser SP; Huang DCS; Roberts AW; Guthridge MA; Wei AH
Leukemia; 2018 Feb; 32(2):303-312. PubMed ID: 28751770
[TBL] [Abstract][Full Text] [Related]
35. Improving chemotherapeutic efficiency in acute myeloid leukemia treatments by chemically synthesized peptide interfering with CXCR4/CXCL12 axis.
Li X; Guo H; Duan H; Yang Y; Meng J; Liu J; Wang C; Xu H
Sci Rep; 2015 Nov; 5():16228. PubMed ID: 26538086
[TBL] [Abstract][Full Text] [Related]
36. [Role of c-Myc in mesenchymal stromal cell-mediated drug resistance in acute leukemia cells].
Xia B; Guo Q; Zhao WP; Guo SQ; Tian C; Zhang YZ
Zhonghua Yi Xue Za Zhi; 2013 Jun; 93(22):1746-9. PubMed ID: 24124686
[TBL] [Abstract][Full Text] [Related]
37. Knockdown of BNIP3L or SQSTM1 alters cellular response to mitochondria target drugs.
Rodrigo R; Mendis N; Ibrahim M; Ma C; Kreinin E; Roma A; Berg S; Blay J; Spagnuolo PA
Autophagy; 2019 May; 15(5):900-907. PubMed ID: 30563411
[TBL] [Abstract][Full Text] [Related]
38. PTEN/AKT signaling mediates chemoresistance in refractory acute myeloid leukemia through enhanced glycolysis.
Ryu MJ; Han J; Kim SJ; Lee MJ; Ju X; Lee YL; Son JH; Cui J; Jang Y; Chung W; Song IC; Kweon GR; Heo JY
Oncol Rep; 2019 Nov; 42(5):2149-2158. PubMed ID: 31545464
[TBL] [Abstract][Full Text] [Related]
39. De novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related changes.
Lopes MR; Pereira JK; de Melo Campos P; Machado-Neto JA; Traina F; Saad ST; Favaro P
Sci Rep; 2017 Jan; 7():40707. PubMed ID: 28084439
[TBL] [Abstract][Full Text] [Related]
40. CXCR4-mediated signaling regulates autophagy and influences acute myeloid leukemia cell survival and drug resistance.
Hu X; Mei S; Meng W; Xue S; Jiang L; Yang Y; Hui L; Chen Y; Guan MX
Cancer Lett; 2018 Jul; 425():1-12. PubMed ID: 29574276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
